- Home
- LRMR vs SLP Comparison
LRMR vs SLP Comparison
Compare LRMR & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- SLP
- Stock Information
- Founded
- LRMR N/A
- SLP 1996
- Country
- LRMR United States
- SLP United States
- Employees
- LRMR N/A
- SLP N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- SLP EDP Services
- Sector
- LRMR Health Care
- SLP Technology
- Exchange
- LRMR Nasdaq
- SLP Nasdaq
- Market Cap
- LRMR 332.1M
- SLP 322.4M
- IPO Year
- LRMR N/A
- SLP 1997
- Fundamental
- Price
- LRMR $3.45
- SLP $17.81
- Analyst Decision
- LRMR Strong Buy
- SLP Buy
- Analyst Count
- LRMR 7
- SLP 8
- Target Price
- LRMR $16.71
- SLP $26.80
- AVG Volume (30 Days)
- LRMR 1.8M
- SLP 420.8K
- Earning Date
- LRMR 11-05-2025
- SLP 12-01-2025
- Dividend Yield
- LRMR N/A
- SLP N/A
- EPS Growth
- LRMR N/A
- SLP N/A
- EPS
- LRMR N/A
- SLP N/A
- Revenue
- LRMR N/A
- SLP $80,383,000.00
- Revenue This Year
- LRMR N/A
- SLP $13.67
- Revenue Next Year
- LRMR N/A
- SLP $1.50
- P/E Ratio
- LRMR N/A
- SLP N/A
- Revenue Growth
- LRMR N/A
- SLP 20.01
- 52 Week Low
- LRMR $1.61
- SLP $12.39
- 52 Week High
- LRMR $9.50
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- LRMR 39.35
- SLP 59.84
- Support Level
- LRMR $3.16
- SLP $16.41
- Resistance Level
- LRMR $4.50
- SLP $18.95
- Average True Range (ATR)
- LRMR 0.30
- SLP 0.91
- MACD
- LRMR -0.10
- SLP -0.02
- Stochastic Oscillator
- LRMR 24.09
- SLP 66.31
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.